• Home
  • Overview
    • Results of the early benefit assessment
      • G-BA procedures
      • Resolutions
      • Subpopulations
    • Indication areas (G-BA)
      • Eye diseases
      • Skin diseases
      • Cardiovascular diseases
      • Infectious diseases
      • Respiratory system diseases
      • Hematopoietic diseases
      • Musculoskeletal system diseaeses
      • Nervous system diseases
      • Genitourinary system diseases
      • Digestive system diseases
      • Oncological diseases
      • Mental illnesses
      • Metabolic diseases
      • Other diseases
      • Orphan drugs
    • Results of reassessments
      • G-BA request (§13 VerfO)
      • Manufacturer's request (§14 VerfO)
      • Orphan drugs, exceeding turnover limit
      • Orphan drugs, loss of status
    • G-BA requirements
  • Procedures
    • G-BA resolutions
    • G-BA active procedures
    • G-BA procedures not completed
  • Fundamentals
    • AMNOG step by step
      • Detailed analysis for each G-BA resolution
      • Interactive analysis
      • Interactive analysis: Excel export
      • Interactive analysis: Bookmarks
      • Interactive analysis: dimensions
      • Intelligent search
      • Monthly report
      • AMNOG app
      • Calculation methods
    • EMA regulatory procedure
    • Changes in legal regulations
    • Technical terms English-German
  • Contact
    • Contact form
    • Legal notice
    • Privacy policy
Logo AMNOG.de
Search G-BA resolutions

Login

Login
  • Deutsch
  • English
  • Recent price changes
  • Arbitration results
  • Discontinuations
  • Special practice conditions
  • AM-RL Appendix III: Prescription exclusions
  • AM-RL Appendix VI: Off-label Use
  • AM-RL Appendix VIIa: Biosimilars
  • AM-RL Appendix XIIa: Combination discounts
AMNOG > AM-RL Appendix VI: Off-label Use